Paris-based biotech startup Phagos, which develops AI-driven phage therapies for bacterial infections, has raised €25 million in a Series A round co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter to fuel its global expansion across Europe, Asia, and the Americas.
- Established in 2021 by Alexandros Pantalis and Dr. Adèle James, Phagos develops bacteriophage-based treatments to combat bacterial diseases, focusing initially on veterinary applications.
- The company combines microbiology and artificial intelligence through its Alphagos platform to identify and design phages, viruses that specifically target harmful bacteria such as Salmonella, E. coli, and Enterococcus cecorum.
- These phages are selected from the environment and formulated into personalized treatments that attack only the intended bacteria, leaving other cells unaffected. Phagos’ approach allows treatments to be continuously updated to address evolving bacterial resistance, offering an alternative to conventional antibiotics.
- The firm’s solutions are currently deployed across poultry, cattle, swine, and shrimp sectors, aiming to reduce mortality from bacterial infections and curb the rise of antimicrobial resistance.
Details of the deal
- The €25 million Series A round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter, with additional participation from Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.
“Phagos’ pioneering platform provides a high efficiency alternative to antibiotics, offering a promising solution to a major global health crisis. This investment will help the company become a category-defining leader, reshaping how bacterial infections are treated with a transformative impact on both animal and human health in a massive global market," claims Rob Kniaz, founder and Emeritus Partner of Hoxton Ventures.
- With the fresh €25 million in capital, Phagos plans to expand the deployment of its veterinary phage therapy solutions, enhance its patented AI-driven phage discovery platform, and accelerate international growth across Europe, Asia, and the Americas.
- The funding will also support team expansion, reinforcing its scientific and technical expertise to advance R&D and scale operations.
"This funding gives us the means to accelerate our mission and make this alternative accessible, fast, and effective against the rise of bacterial resistance. Thanks to our regulatory breakthroughs and our patented platform combining microbiology and artificial intelligence, we now have the opportunity to establish phage therapy as a global reference solution: for animal health today, and for human health tomorrow,” said Alexandros Pantalis and Adèle James, co-founders of Phagos.
